Craig-Hallum upgraded CareDx to a Buy rating and raised its price target to $64 per share, citing growth drivers tied to reimbursement momentum and assay expansion. The analyst pointed to CareDx’s acquisition of Naveris and said expanded coverage and approved indications could lift near- and long-term results. Craig-Hallum highlighted CareDx’s transplant testing economics and discussed expectations that the AlloSure Kidney assay could win approvals beyond detecting rejection, including subclinical injury, prognosis, and therapy decision-making. The note also cited HeartCare usage improvements tied to a local coverage determination and supportive evidence from peer-reviewed studies. The analyst further suggested NavDx could contribute to volume growth and outlined a timeline for other pipeline products, positioning AlloSure and HeartCare adoption as the primary catalysts for the updated outlook.